• linkedin
  • Increase Font
  • Sharebar

    Uro Pipeline: FDA grants priority review to advanced bladder Ca agent


    License agreement signed for use of stem cells in treating infertility

    Creative Medical Technologies, Inc. has announced the signing of a license agreement with LA BioMed granting exclusive rights for United States patent application #14/508763, covering the use of stem cells for treatment of male infertility. In the patent application and a subsequent publication, Ronald S. Swerdloff, MD, an LA BioMed lead researcher, demonstrated that the administration of bone marrow cells into the testicles of mice with chemically induced damage to sperm-producing cells led to the generation of new sperm-producing cells.


    First patient enrolled, treated in trial of urinary incontinence agent

    The first patient has been enrolled and treated in the ADRESU trial, a late-phase, physician-initiated Japanese clinical trial to study the efficacy and safety of Cytori Cell Therapy in men with urinary incontinence after prostatic surgery for prostate cancer or BPH. ADRESU is a multicenter, 45-patient open-label controlled trial of the ECCI-50 cellular therapeutic and is based on promising pilot trial data published in the International Journal of Urology (2014; 21:294-300). The primary endpoint for the ADRESU trial will be the number of patients who experience reduction of urinary leakage volume (as measured by the weight of diaper pads used over 24 hours) 52 weeks after treatment, according to developer Cytori Therapeutics, Inc.

    More from Urology Times:

    Words of wisdom: ‘Patients don’t choose when they get sick’

    Concomitant Ra 223, abiraterone found safe, effective

    Early fulguration may be best for radiation cystitis

    Subscribe to Urology Times to get monthly news from the leading news source for urologists.

    Benjamin P. Saylor
    Saylor is content managing editor for Urology Times.


    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available